CONTINUOUS LISURIDE EFFECTS ON CENTRAL DOPAMINERGIC MECHANISMS IN PARKINSONS-DISEASE

被引:76
|
作者
BARONTI, F [1 ]
MOURADIAN, MM [1 ]
DAVIS, TL [1 ]
GIUFFRA, M [1 ]
BRUGHITTA, G [1 ]
CONANT, KE [1 ]
CHASE, TN [1 ]
机构
[1] NINCDS, EXPTL THERAPEUT BRANCH,BLDG 10,ROOM 5C103, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA
关键词
D O I
10.1002/ana.410320611
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Effects of the long term, continuous administration of a dopamine agonist on motor response complications attending levodopa therapy were studied in 7 patients with advanced Parkinson's disease under controlled conditions. After a 3-month round-the-clock infusion of lisuride, the duration of antiparkinsonian action of levodopa increased by approximately 90%, and the therapeutic window for the acutely administered dopamine precursor widened by >300%. These benefits were more than three times greater than those produced by 9 days of continuous levodopa administration. In contrast to the effects on levodopa pharmacodynamics, the continuous infusion of lisuride did not prolong its action, suggesting a lisuride effect on presynaptic as well as postsynaptic dopaminergic mechanisms. These results lend further support to the view that continuous dopamine replacement ameliorates motor fluctuations and peak-dose dyskinesias that complicate standard levodopa regimens. Our findings further suggest that alterations at both presynaptic and postsynaptic levels contributing to these motor complications tend to normalize with the more physiological stimulation afforded by continuous replacement strategies, especially when given chronically.
引用
收藏
页码:776 / 781
页数:6
相关论文
共 50 条
  • [31] CENTRAL MECHANISMS AND LEVODOPA RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE
    MOURADIAN, MM
    CHASE, TN
    CLINICAL NEUROPHARMACOLOGY, 1988, 11 (04) : 378 - 385
  • [32] PROBLEMS IN DAILY MOTOR PERFORMANCES IN PARKINSONS-DISEASE - THE CONTINUOUS DOPAMINERGIC STIMULATION
    STOCCHI, F
    RUGGIERI, S
    BRUGHITTA, G
    AGNOLI, A
    JOURNAL OF NEURAL TRANSMISSION, 1986, : 209 - 218
  • [33] PARKINSONS-DISEASE AND CONTINUOUS INFUSION OF DOPAMINERGIC AGONISTS - THE ROLE OF A-DIHYDROERGOCRYPTINE
    STOCCHI, F
    RUGGIERI, S
    BRAGONI, M
    GIORGI, L
    BRAVI, D
    CARTA, A
    AGNOLI, A
    NEW TRENDS IN CLINICAL NEUROPHARMACOLOGY: CALCIUM ANATONISTS, ACUTE NEUROLOGY, HEADACHE AND MOVEMENT DISORDERS, 1988, 7 : 262 - 267
  • [34] DOPAMINERGIC AGONISTS IN THE TREATMENT OF PARKINSONS-DISEASE
    GOETZ, CG
    DIEDERICH, NJ
    NEUROLOGIC CLINICS, 1992, 10 (02) : 527 - 540
  • [35] DOPAMINERGIC HALLUCINOSIS WITH FLUOXETINE IN PARKINSONS-DISEASE
    LAUTERBACH, EC
    AMERICAN JOURNAL OF PSYCHIATRY, 1993, 150 (11): : 1750 - 1750
  • [36] DOPAMINERGIC AGONISTS IN THE TREATMENT OF PARKINSONS-DISEASE
    GOETZ, CG
    NEUROLOGY, 1990, 40 (10) : 50 - 54
  • [37] DOPAMINERGIC NERVOUS TRANSMISSION IN PARKINSONS-DISEASE
    RINNE, UK
    SONNINEN, V
    RIEKKINEN, P
    LAAKSONEN, H
    MEDICAL BIOLOGY, 1974, 52 (03): : 208 - 217
  • [38] TUBEROINFUNDIBULAR DOPAMINERGIC FUNCTION IN PARKINSONS-DISEASE
    FRANCESCHI, M
    CAMERLINGO, M
    PEREGO, L
    BOTTACCHI, E
    TRUCI, G
    MAMOLI, A
    EUROPEAN NEUROLOGY, 1988, 28 (03) : 117 - 119
  • [39] MANIPULATING THE DOPAMINERGIC SYSTEM IN PARKINSONS-DISEASE
    LANG, AE
    PHARMACOLOGY & THERAPEUTICS, 1987, 32 (01) : 51 - 76
  • [40] BRAIN DOPAMINERGIC MECHANISMS IN PARKINSONS-DISEASE EVALUATED BY POSITRON EMISSION TOMOGRAPHY
    AQUILONIUS, SM
    LANGSTROM, B
    TEDROFF, J
    ACTA NEUROLOGICA SCANDINAVICA, 1989, 80 : 55 - 59